menu
    • menu
    [{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Eris Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Divestment","leadProduct":"Salicylic Acid","moa":"COX-1","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Eris Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Eris Pharmaceuticals"},{"orgOrder":0,"company":"NovaBay Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Salicylic Acid","moa":"COX-1","graph1":"Dermatology","graph2":"Approved FDF","graph3":"NovaBay Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"NovaBay Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"NovaBay Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Asalyxa Bio","sponsor":"Orange Grove Bio","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"Salicylic Acid","moa":"COX-1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Asalyxa Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Asalyxa Bio \/ Orange Grove Bio","highestDevelopmentStatusID":"4","companyTruncated":"Asalyxa Bio \/ Orange Grove Bio"},{"orgOrder":0,"company":"Asalyxa Bio","sponsor":"Research Bridge Partners","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Financing","leadProduct":"Salicylic Acid","moa":"COX-1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Asalyxa Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Asalyxa Bio \/ Research Bridge Partners","highestDevelopmentStatusID":"4","companyTruncated":"Asalyxa Bio \/ Research Bridge Partners"}]

    Find Clinical Drug Pipeline Developments & Deals for ortho Hydroxybenzoic Acid

    Menu

    ortho Hydroxybenzoic Acid

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Dr. Reddy's Laboratories

                            India
                            MAGHREB PHARMA
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

                            Lead Product(s) : Salicylic Acid

                            Therapeutic Area : Dermatology

                            Study Phase : Approved FDF

                            Sponsor : Eris Pharmaceuticals

                            Deal Size : $33.2 million

                            Deal Type : Divestment

                            DEALS_DEV arrow-down

                            Dr. Reddy’s Divests Certain Non-Core Brands in Dermatology in India to Eris Lifesciences to Focus on Strengt...

                            Details : Under the agreement, Dr. Reddy’s divests certain non-core brands including Hydroheal, Gris ODT, Revilus, Revibra, Avarta, Salicylix (salicylic acid), Clearz, Acrofy and Aquaderm, in dermatology in India to Eris Lifesciences.

                            Product Name : Salicylix

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            March 16, 2023

                            Lead Product(s) : Salicylic Acid

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved FDF

                            Sponsor : Eris Pharmaceuticals

                            Deal Size : $33.2 million

                            Deal Type : Divestment

                            Dr Reddy Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            NovaBay Pharmaceuticals

                            U.S.A arrow
                            World Vaccine Conference
                            Not Confirmed

                            NovaBay Pharmaceuticals

                            U.S.A arrow
                            World Vaccine Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Salicylic Acid

                            Therapeutic Area : Dermatology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            NovaBay Pharmaceuticals Launches DERMAdoctor’s New Comfort + Joy Psoriasis Therapeutic Moisturizing Cream on...

                            Details : Salicylic acid helps soften, lift, and clear away flakes of skin on psoriasis plaques. It helps to control the symptoms of psoriasis and provides relief from itching, irritation and redness.

                            Product Name : DERMAdoctor

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            April 21, 2023

                            Lead Product(s) : Salicylic Acid

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Asalyxa Bio

                            U.S.A arrow
                            World Vaccine Conference
                            Not Confirmed

                            Asalyxa Bio

                            U.S.A arrow
                            World Vaccine Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Salicylic Acid

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Preclinical

                            Sponsor : Research Bridge Partners

                            Deal Size : $2.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Asalyxa Bio Closes Seed Financing to Advance Lead Program into First-in-Human Clinical Studies

                            Details : Proceeds from the financing will be used to advance Asalyxa Bio's lead development candidate, ASX-100, into first-in-human clinical trials.

                            Product Name : ASX-100

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            February 23, 2021

                            Lead Product(s) : Salicylic Acid

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Research Bridge Partners

                            Deal Size : $2.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Asalyxa Bio

                            U.S.A arrow
                            World Vaccine Conference
                            Not Confirmed

                            Asalyxa Bio

                            U.S.A arrow
                            World Vaccine Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Salicylic Acid

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Preclinical

                            Sponsor : Orange Grove Bio

                            Deal Size : Undisclosed

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Asalyxa Bio Launches with Novel Neutrophil-Targeting Drug Delivery Platform Technology and Lead Candidate, ASX...

                            Details : ASX-100 is a novel, spherical polymer particle that degrades into salicylic acid – an active metabolite of aspirin – and a food additive that is listed as GRAS (generally regards as safe) by the FDA. Seed funding will be used in first-in-human trials...

                            Product Name : ASX-100

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            August 25, 2020

                            Lead Product(s) : Salicylic Acid

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Orange Grove Bio

                            Deal Size : Undisclosed

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth